呋喹替尼Q2海外销售额达119亿日元

文章预览

FY2024 Q1 Revenue JPY 11.9B (Newly Launched) Continued strong uptake following U.S. FDA approval in November 2023 for metastatic colorectal cancer (mCRC) patients previously treated with certain anti-cancer medicines. Additional regulatory applications progressing as expected; approved in EU in June 2024, with regulatory approval decision in Japan expected in FY2024. ………………………………